Clinical Trial Update: A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI [Phase 3]

View source ↗

Summary

The Phase 3 trial comparing AC0010 to standard chemotherapy in advanced non-small cell lung cancer after progression on EGFR inhibitors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AC0010
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Conditions: NSCLC | Phase 3 | Status: WITHDRAWN